Journal of Orthopedic Research and Therapy (ISSN: 2575-8241)

Article / brief report

"Atypical Femur Fracture: Premonitory Data"

Natalia Bravo Martin1, Moises Alonso Gregorio2, Rosa Arboiro Pinel3, Manuel Díaz Curiel3*

1Department of Internal Medicine, Hospital La Luz, Madrid, Spain

2Department of Urgency, Hospital Ramón y Cajal, Madrid, Spain

3Department of Internal Medicine, Metabolic Bone Diseases Unit, Hospital Fundación Jiménez Díaz, Madrid, Spain

*Corresponding author: Manuel Diaz Curiel, Department of Internal Medicine, Metabolic Bone Diseases Unit, Hospital Fundación Jiménez Díaz, Madrid, Spain

Received Date: 11 February, 2021; Accepted Date: 16 February, 2021; Published Date: 19 February, 2021


Background

Bisphosphonates (BPN) have shown a clear evidence for reducing the incidence of fractures in post-menopausal women with osteoporosis [1], but it has been observed that its use for years is not exempt from complications. Continued administration of BPN may cause a paradoxical effect like osteonecrosis of the mandible, frequently after a dental surgery. An interest has emerged about the association between the use of BPN and Atypical Femur Fractures (AFF); a type of fracture that occurs below the great trocanter atraumatic or after a minimal trauma, with a rate of 3.2- 50 cases per 10,000 person-years. The physiopathology of these fractures is unknown but they may be due to the prolonged halflife of BPN and their effect on fracture remodeling (microdamage accumulation, alternations to the normal pattern of collagen crosslinking,reduced vascularity, antiagiogenic effects, etc), which disturbs the mineralization process with the consequent affectation of bone quality [2]. There are some risk factors like sex (women), race (Asian), femoral geometry (varus alignment, smaller canal and larger offset) and continuous treatment with BPN for years [3].

Some comorbid conditions (e.g., vitamin-D deficiency, rheumatoid arthritis, cancer disease, hypophosphatasia) and use of pharmaceutical agents (e.g., s, glucocorticoids, proton pump inhibitors) add more information about which kind of patient has higher risk to suffer from complications of the treatment of BPN [4]. After 5 years of treatment with BPN, the risk of AFF increases significantly and decreases after cessation; Therefore, it´s important to evaluate patients in treatment with BPN for a long period of time in order to avoid possible adverse effects. Patients with AFF may discontinue BP therapy once the diagnosis of AFFs is established and PTH is the treatment more recommended [5]. Cortical thickening and periosteal reaction of lateral cortex could be premonitory data of AFF, which could help us to remove a treatment with BPN and avoid these types of fractures.

Discussion

Nowadays there is no concrete indication for the duration of BPN treatment. Nevertheless, for long periods of treatments, we recommend annual re-evaluation considering fracture history, newly diagnosed disorders, bone turnover markers and BMD determination [2,5]. Appearance of prodromal symptoms like pain in the thighs and radiographic features such as cortical thickening could be considered premonitory factors of an atypical fracture, so we should consider the continuation of treatment with BPN [2]. Tejwani and Peck published that anterior-posterior and lateral radiographs are reliable for distinguishing between femoral fractures related to bisphosphonates use and those not related to such use [6]. The decision to reintroduce or withdraw the treatment should be individualized. AFF has also been reported after treatment with others antiresorptives such as Denosumab [7-9].

Conclusion

Bisphosphonates are an effective treatment for patients with osteoporosis, but their use is associated with a rare condition: Atypical femur fractures, with an unclear pathogenesis. This type of complication is uncommon and if we consider predictive factors such as cortical thickening, a large number of them could be avoided. In short, physicians and patients should know the possibility of AFF in order to assess the risk-benefit of continuing/ withdrawing treatment with bisphosphonates.



Citation: Martin NB, Gregorio MA, Pinel RA, Curiel M by Bravo N, Alonso M, Arboiro R, Diaz-Curiel M. (2021) Atypical Femur Fracture: Premonitory Data. J Orthop Res Ther 6: 1185. DOI: 10.29011/2575-8241.001185

free instagram followers instagram takipçi hilesi